Core Viewpoint - Duori Pharmaceutical announced on October 24 that the share transfer requires approval from the company's shareholders meeting and compliance confirmation from the Shenzhen Stock Exchange, highlighting the need for adherence to legal procedures and information disclosure obligations to protect the interests of the company and minority investors [1] Summary by Relevant Sections - Share Transfer Process - The share transfer is subject to approval from the shareholders meeting and may require additional regulatory approvals [1] - Compliance and Legal Obligations - The company emphasizes the importance of following relevant laws and regulations in the process, ensuring that all legal procedures are strictly adhered to [1] - Investor Communication - Duori Pharmaceutical will keep investors informed of any developments through official announcements, reinforcing its commitment to transparency [1]
多瑞医药：本次股份转让尚需上市公司股东会审议通过相关事项